[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565183":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":36,"locations":45,"responsibleParty":98,"collaborators":100,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":120,"minAge":121,"maxAge":10,"enrollmentInfo":122,"targetDuration":125,"studyType":126,"phases":10,"briefSummary":127,"conditions":128,"keywords":134,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AIgorithm-classified PDAC Group",null,"Participants who underwent non-contrast abdominal and\u002For chest CT scans and were preliminarily classified by the aIgorithm as PDAC.",[13],"Diagnostic Test: PDAC",{"label":15,"type":10,"description":16,"interventionNames":17},"AIgorithm-classified Pancreatic Precursor Lesions Group","Participants who underwent non-contrast abdominal and\u002For chest CT scans and were preliminarily classified by the aIgorithm as pancreatic precursor lesions.",[18],"Diagnostic Test: Pancreatic precursor lesions",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","PDAC","Participants with algorithm-identified PDAC will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT\u002FMRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Pancreatic precursor lesions","Participants with algorithm-identified pancreatic precursor lesions will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT\u002FMRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.",[15],[30,33],{"name":31,"affiliation":5,"role":32},"Jin Gang, M.D.","STUDY_CHAIR",{"name":34,"affiliation":5,"role":35},"Wang Bei Lei, M.D.","STUDY_DIRECTOR",[37,41],{"name":34,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","86-13774238083","lilly_wang@126.com",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Guo Shi Wei, M.D.","86-18621500666","gestwa@163.com",[46,67,83],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Shanghai Changhai Hospital","RECRUITING","Shanghai","Shanghai Municipality","200433","China","CN",{"type":55,"coordinates":56},"Point",[57,58],121.45806,31.22222,{"lat":58,"lon":57},[61,63,65],{"name":62,"role":38,"phone":39,"phoneExt":10,"email":40},"Wang Beilei, M.D.",{"name":31,"role":64,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":34,"role":66,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":68,"status":48,"city":69,"state":70,"zip":71,"country":52,"countryCode":53,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Second Affiliated Hospital of Jiaxing University","Jiaxing","Zhejiang","314000",{"type":55,"coordinates":73},[74,75],120.75,30.7522,{"lat":75,"lon":74},[78,82],{"name":79,"role":38,"phone":80,"phoneExt":10,"email":81},"Shen Yi Jue, M.D.","13605835645","dr.syj@163.com",{"name":79,"role":64,"phone":10,"phoneExt":10,"email":10},{"facility":84,"status":48,"city":85,"state":70,"zip":86,"country":52,"countryCode":53,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Yinzhou Hospital Affiliated to Medical School of Ningbo University","Ningbo","315100",{"type":55,"coordinates":88},[89,90],121.54945,29.87819,{"lat":90,"lon":89},[93,97],{"name":94,"role":38,"phone":95,"phoneExt":10,"email":96},"Zhu Ke Lei, M.D.","13566636272","dr.zkl@163.com",{"name":94,"role":64,"phone":10,"phoneExt":10,"email":10},{"type":99,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[101,102,104,107,109],{"name":84,"class":6},{"name":103,"class":6},"The Second Affiliated Hospital of Jiaxing University",{"name":105,"class":106},"Central Hospital of Lishui City","UNKNOWN",{"name":108,"class":106},"Jingning County People's Hospital",{"name":110,"class":106},"Alibaba DAMO Academy","100565183","ai-powered-early-detection-for-pancreatic-cancer-via-non-contrast-ct-in-opportunistic-screening-cohort-100565183",false,"NCT06638866","AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort","Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer","AI-PANC","Inclusion Criteria\n\n1\\. Individuals undergoing routine non-contrast chest and\u002For abdominal CT scans for non-pancreatic indications.\n\nExclusion Criteria\n\n1. History of pancreatic cancer;\n2. History of thoracic or abdominal surgery;\n3. Acute pancreatitis within 6 months;\n4. Patients referred for evaluation of suspected or confirmed pancreatic cancer.",true,"ALL","18 Years",{"count":123,"type":124},5000,"ESTIMATED","5 Years","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III\u002FIV in \\>80% of cases). This prospective, observational, multi-center study will evaluate the performance of an AI-powered opportunistic screening system utilizing non-contrast computed tomography (NCCT) acquired during routine clinical encounters or health check-ups. The proposed AI model will perform automated detection of pancreatic parenchymal abnormalities, including PDAC and precursor lesions (intraductal papillary mucinous neoplasms \\[IPMN\\], mucinous cystic neoplasms \\[MCN\\]). Algorithm-positive cases will be independently reviewed by two radiologists. Highly suspected individuals will undergo further diagnostic verification, including serological tests and multimodal imaging confirmation. Patients with confirmed positive diagnosis will receive multidisciplinary consultation and specialized treatment, whereas those with negative results will undergo at least one-year clinical follow-up. This study will quantitatively evaluate the AI system's performance, and aims to advance PDAC early detection, improve patient outcomes, and make it accessible in underserved populations.",[129,130,131,132,133],"Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma","Pancreatic Intraepithelial Neoplasias","Intraductal Papillary Mucinous Neoplasm","Mucinous Cystic Neoplasm",[135,136,137,129,138,22,139],"Early Screening","Early Diagnosis","Artificial Intelligence","Pancreatic Lesion","Non-contrast CT","2025-03-14",{"date":142,"type":143},"2025-03-19","ACTUAL",{"date":145,"type":143},"2024-08-03",{"date":147,"type":124},"2030-12-31",{"name":5,"class":6},3]